Goin Kathleen

COO Goin sold all 4,302 shares for $547.4K (blended $127.24/share) on 2026-04-15 across 5 separate sales

Chief Operating Officer Kathleen Goin executed 5 separate sales totaling 4,302 shares for $547,398.98, liquidating her entire shareholding at an average price of $127.24 per share on 2026-04-15. The current stock price of $130.01 sits 12.4% below the 52-week high of $148.34, while posting a 30-day gain of +13.8% and 90-day gain of +30.4%, indicating recent strength. The company remains unprofitable with quarterly revenue of $0.00 and net income of $-11,345,000.00, though annual revenue growth reached +65.3% year-over-year. Goin's prior three sales at PVLA on 2026-03-18 all showed positive 30-day outcomes (ranging +9.2% to +10.6%), though 90-day results are not yet measurable for those trades, and her cross-ticker track record shows 3 prior sells with an average 30-day return of +9.9%.

COO Kathleen Goin liquidates entire 4,302-share position for $507,610.99 across 3 sales on 2026-03-18

Kathleen Goin, Chief Operating Officer of Palvella Therapeutics, executed three separate sales on March 18, 2026, totaling 4,302 shares for $507,610.99 at an average price of $117.99. The transaction represents a complete exit from her shareholding position, with holdings falling from 4,302 shares to 0 shares post-transaction. This liquidation occurs while the stock trades at $112.50, down 24.2% from its 52-week high of $148.34 but up 41.3% over the prior 30 days. The company reported a net loss of $-11,345,000.00 in the latest period and remains unprofitable despite 65.3% annual revenue growth. The complete divestiture by a C-suite executive warrants examination of whether it reflects operational or financial developments at the company.